Regulus Therapeutics Inc (NASDAQ: RGLS) open the trading on Thursday, with great promise as it jumped 16.28% to $1.50, before settling in for the price of $1.29 at the close. Taking a more long-term approach, RGLS posted a 52-week range of $0.83-$3.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -10.71%. Meanwhile, its Annual Earning per share during the time was 40.21%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -42.89%. This publicly-traded company’s shares outstanding now amounts to $65.50 million, simultaneously with a float of $53.18 million. The organization now has a market capitalization sitting at $99.37 million. At the time of writing, stock’s 50-day Moving Average stood at $1.2806, while the 200-day Moving Average is $1.5596.
Regulus Therapeutics Inc (RGLS) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Regulus Therapeutics Inc’s current insider ownership accounts for 19.71%, in contrast to 63.69% institutional ownership. According to the most recent insider trade that took place on Jan 30 ’25, this organization’s Chief Executive Officer bought 50,000 shares at the rate of 1.09, making the entire transaction reach 54,260 in total value, affecting insider ownership by 260,808. Preceding that transaction, on Jan 30 ’25, Company’s Director bought 19,610 for 1.06, making the whole transaction’s value amount to 20,787. This particular insider is now the holder of 22,169 in total.
Regulus Therapeutics Inc (RGLS) Earnings and Revenue Records
Regulus Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -42.89% and is forecasted to reach -1.39 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -3.70% through the next 5 years, which can be compared against the 40.21% growth it accomplished over the previous five years trading on the market.
Regulus Therapeutics Inc (NASDAQ: RGLS) Trading Performance Indicators
Let’s observe the current performance indicators for Regulus Therapeutics Inc (RGLS). It’s Quick Ratio in the last reported quarter now stands at 10.52. The Stock has managed to achieve an average true range (ATR) of 0.16.
In the same vein, RGLS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.88, a figure that is expected to reach -0.24 in the next quarter, and analysts are predicting that it will be -1.39 at the market close of one year from today.
Technical Analysis of Regulus Therapeutics Inc (RGLS)
[Regulus Therapeutics Inc, RGLS] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 30.08% While, its Average True Range was 0.1836.
Raw Stochastic average of Regulus Therapeutics Inc (RGLS) in the period of the previous 100 days is set at 54.91%, which indicates a major rise in contrast to 29.49% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 106.60% that was higher than 83.60% volatility it exhibited in the past 100-days period.
